-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Vericel Co. (NASDAQ:VCEL) Shares Acquired by GW&K Investment Management LLC
Vericel Co. (NASDAQ:VCEL) Shares Acquired by GW&K Investment Management LLC
GW&K Investment Management LLC lifted its holdings in shares of Vericel Co. (NASDAQ:VCEL – Get Rating) by 169.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 907,249 shares of the biotechnology company's stock after buying an additional 571,139 shares during the quarter. GW&K Investment Management LLC owned approximately 1.93% of Vericel worth $34,676,000 as of its most recent SEC filing.
Other large investors have also made changes to their positions in the company. State Street Corp increased its position in shares of Vericel by 12.3% during the fourth quarter. State Street Corp now owns 2,809,660 shares of the biotechnology company's stock worth $110,420,000 after purchasing an additional 307,755 shares in the last quarter. Conestoga Capital Advisors LLC raised its stake in Vericel by 54.7% during the first quarter. Conestoga Capital Advisors LLC now owns 2,596,810 shares of the biotechnology company's stock worth $99,250,000 after purchasing an additional 918,299 shares during the period. Fisher Asset Management LLC raised its stake in Vericel by 18.9% during the fourth quarter. Fisher Asset Management LLC now owns 1,236,675 shares of the biotechnology company's stock worth $48,601,000 after purchasing an additional 196,635 shares during the period. Geode Capital Management LLC raised its stake in Vericel by 1.3% during the fourth quarter. Geode Capital Management LLC now owns 810,974 shares of the biotechnology company's stock worth $31,871,000 after purchasing an additional 10,108 shares during the period. Finally, New York State Common Retirement Fund raised its stake in shares of Vericel by 9.3% in the 1st quarter. New York State Common Retirement Fund now owns 785,567 shares of the biotechnology company's stock valued at $30,024,000 after acquiring an additional 66,771 shares during the period.
Get Vericel alerts:Wall Street Analyst Weigh In
A number of equities research analysts have recently issued reports on the stock. BTIG Research reduced their price target on shares of Vericel from $45.00 to $34.00 and set a "buy" rating on the stock in a research note on Monday, July 18th. Truist Financial cut their price target on Vericel to $33.00 in a research note on Friday, July 22nd. One investment analyst has rated the stock with a sell rating and three have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $37.33.
Vericel Price Performance
Shares of NASDAQ VCEL opened at $29.84 on Tuesday. Vericel Co. has a 1-year low of $22.42 and a 1-year high of $60.24. The company has a market cap of $1.41 billion, a PE ratio of -82.89 and a beta of 1.98. The stock has a fifty day moving average price of $27.11 and a 200 day moving average price of $31.61.Vericel Company Profile
(Get Rating)
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns.
Recommended Stories
- Get a free copy of the StockNews.com research report on Vericel (VCEL)
- Home Depot, Lowe's On Track To Grow 2022 Earnings
- Could Smaller be Better for Investors in Norwegian Cruise Lines?
- Walmart Or Target: Which Is The Stronger Stock?
- Can Etsy Continue to Thrive After the Pandemic?
- Volume Surges Spark Turnarounds for These 3 Stocks
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.
GW&K Investment Management LLC lifted its holdings in shares of Vericel Co. (NASDAQ:VCEL – Get Rating) by 169.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 907,249 shares of the biotechnology company's stock after buying an additional 571,139 shares during the quarter. GW&K Investment Management LLC owned approximately 1.93% of Vericel worth $34,676,000 as of its most recent SEC filing.
GW&K Investment Management LLC在最近提交給美國證券交易委員會(Securities and Exchange Commission,簡稱:美國證券交易委員會)的13F文件中稱,該公司第一季度將持有的Vericel Co.股票增持了169.9%。該公司在本季度額外購買了571,139股後,擁有這家生物技術公司的907,249股股票。截至最近提交的美國證券交易委員會申請文件,GW&K投資管理公司擁有Vericel約1.93%的股份,價值34,676,000美元。
Other large investors have also made changes to their positions in the company. State Street Corp increased its position in shares of Vericel by 12.3% during the fourth quarter. State Street Corp now owns 2,809,660 shares of the biotechnology company's stock worth $110,420,000 after purchasing an additional 307,755 shares in the last quarter. Conestoga Capital Advisors LLC raised its stake in Vericel by 54.7% during the first quarter. Conestoga Capital Advisors LLC now owns 2,596,810 shares of the biotechnology company's stock worth $99,250,000 after purchasing an additional 918,299 shares during the period. Fisher Asset Management LLC raised its stake in Vericel by 18.9% during the fourth quarter. Fisher Asset Management LLC now owns 1,236,675 shares of the biotechnology company's stock worth $48,601,000 after purchasing an additional 196,635 shares during the period. Geode Capital Management LLC raised its stake in Vericel by 1.3% during the fourth quarter. Geode Capital Management LLC now owns 810,974 shares of the biotechnology company's stock worth $31,871,000 after purchasing an additional 10,108 shares during the period. Finally, New York State Common Retirement Fund raised its stake in shares of Vericel by 9.3% in the 1st quarter. New York State Common Retirement Fund now owns 785,567 shares of the biotechnology company's stock valued at $30,024,000 after acquiring an additional 66,771 shares during the period.
其他大型投資者也改變了他們在該公司的頭寸。道富銀行在第四季度增持了Vericel股票的頭寸12.3%。道富集團目前持有這家生物技術公司2,809,660股股票,價值110,420,000美元,此前該公司在上個季度又購買了307,755股。Conestoga Capital Advisors LLC在第一季度將其在Vericel的持股增加了54.7%。Conestoga Capital Advisors LLC現在擁有這家生物技術公司2,596,810股股票,價值99,250,000美元,在此期間又購買了918,299股。Fisher Asset Management LLC在第四季度將其在Vericel的持股增加了18.9%。Fisher Asset Management LLC現在擁有這家生物技術公司1,236,675股股票,價值48,601,000美元,在此期間又購買了196,635股。Geode Capital Management LLC在第四季度將其在Vericel的持股增加了1.3%。Geode Capital Management LLC現在擁有這家生物技術公司810,974股股票,價值31,871,000美元,在此期間又購買了10,108股。最後,紐約州共同退休基金在第一季度將其在Vericel的股份增加了9.3%。紐約州共同退休基金現在擁有這家生物技術公司785,567股股票,價值300,024,000美元,在此期間又購買了66,771股。
Wall Street Analyst Weigh In
華爾街分析師也加入進來
A number of equities research analysts have recently issued reports on the stock. BTIG Research reduced their price target on shares of Vericel from $45.00 to $34.00 and set a "buy" rating on the stock in a research note on Monday, July 18th. Truist Financial cut their price target on Vericel to $33.00 in a research note on Friday, July 22nd. One investment analyst has rated the stock with a sell rating and three have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $37.33.
一些股票研究分析師最近發佈了關於該股的報告。BTIG Research將Vericel的股票目標價從45.00美元下調至34.00美元,並在7月18日星期一的一份研究報告中設定了該股的“買入”評級。7月22日,Truist Financial在一份研究報告中將Vericel的目標價下調至33.00美元。一名投資分析師對該股的評級為賣出,三名分析師對該公司的評級為買入。根據MarketBeat的數據,該股的普遍評級為“適度買入”,平均目標價為37.33美元。
Vericel Price Performance
Vericel性價比
Vericel Company Profile
Vericel公司簡介
(Get Rating)
(獲取評級)
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns.
Vericel公司是一家商業階段的生物製藥公司,在美國從事運動醫學和嚴重燒傷護理市場的細胞療法的研究、開發、製造和分銷。該公司銷售自體細胞治療產品,包括用於修復有症狀的膝部單個或多個全層軟骨缺陷的自體細胞化支架產品Maci,以及用於治療成人和兒童深真皮或全面燒傷患者的永久性皮膚置換人道主義使用設備Epicel。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Vericel (VCEL)
- Home Depot, Lowe's On Track To Grow 2022 Earnings
- Could Smaller be Better for Investors in Norwegian Cruise Lines?
- Walmart Or Target: Which Is The Stronger Stock?
- Can Etsy Continue to Thrive After the Pandemic?
- Volume Surges Spark Turnarounds for These 3 Stocks
- 免費獲取StockNews.com關於Vericel的研究報告(VCEL)
- 家得寶,Lowe‘s有望在2022年實現收益增長
- 對挪威郵輪公司的投資者來説,更小的規模會更好嗎?
- 沃爾瑪和塔吉特:哪隻股票更強?
- 在大流行之後,Etsy能否繼續蓬勃發展?
- 這3只股票成交量飆升,火花回升
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.
接受Vericel Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Vericel和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧